Journal of Neural Transmission

, Volume 109, Issue 4, pp 489–501

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by l-dopa

  • E. R. Brunt
  • D. J. Brooks
  • A. D. Korczyn
  • J.-L. Montastruc
  • F. Stocchi
  • on behalf of the 043 Study Group

DOI: 10.1007/s007020200040

Cite this article as:
Brunt, E., Brooks, D., Korczyn, A. et al. J Neural Transm (2002) 109: 489. doi:10.1007/s007020200040



To compare the safety and efficacy of ropinirole and bromocriptine as adjunct therapy in patients with Parkinson's disease (PD) not optimally controlled by L-dopa.


A randomised, double-blind trial in which 555 patients were assigned to three treatment groups according to the level of daily dosage of L-dopa, presence of motor fluctuations, and use of dopamine agonist before study entry. Patient response was defined as at least a 20% reduction in daily L-dopa dose plus: for patients with no prior treatment and no motor fluctuations, a 20% reduction in UPDRS motor score; for patients with motor fluctuations, a 20% reduction in time spent "off"; and for patients already taking an agonist, an improvement on the CGI scale.


Safety assessments showed no significant differences in the two treatment groups for patients without prior dopamine-agonist therapy. In the group of patients with prior dopamine-agonist therapy, more patients reported adverse events in the ropinirole group (90% versus 79%, p < 0.001). The proportions of responders tended to be higher in ropinirole groups compared with bromocriptine groups and, in the subgroup with motor fluc-tuations, this difference was statistically significant (9.1% versus 0.0%, respectively; p < 0.05).


Both drugs were well tolerated. In patients receiving a relatively high dose of L-dopa and requiring the addition of a dopamine agonist to control motor fluctuations or dyskinesias, ropinirole was significantly more effective than bromocriptine.

Keywords: Parkinson's diseaseropinirolebromocriptinedrug therapy.

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • E. R. Brunt
    • 1
  • D. J. Brooks
    • 2
  • A. D. Korczyn
    • 3
  • J.-L. Montastruc
    • 4
  • F. Stocchi
    • 5
  • on behalf of the 043 Study Group
  1. 1.Department of Neurology, University Hospital, Groningen, The NetherlandsNL
  2. 2.Division of Neuroscience, Imperial College School of Medicine, Hammersmith Hospital, London, United KingdomGB
  3. 3.Sieratzki Chair of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, IsraelIL
  4. 4.Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, FranceFR
  5. 5.Department of Neuroscience and "Neuromed", University "la Sapienza", Rome, ItalyIT